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ABSTRACT 
 
 
  
Transgenic animals are genetically modified organisms whose genomes have been 
integrated with foreign DNA to provide a new phenotype.  This project informs the reader of 
various uses for this technology, and discusses the impact of this controversial technology on 
society.  This IQP weighs potential benefits of specific transgenic animals against legal and 
ethical concerns regarding their use.  The author concludes that transgenesis could provide 
enormous benefits for society, and should be allowed to continue under tight NIH and FDA 
oversight. 
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PROJECT OBJECTIVES 
 
 
The intent of this project was to describe the applications for transgenic animals, and 
examine the impact of this new and controversial technology on society. This IQP explores the 
potential medical, industrial, and educational benefits of transgenic animals. The research also 
illustrates various relationships between the technologies, the ethical concerns of society, and the 
legislation that regulates the use of transgenic animals. Chapter-1 describes how transgenic 
animals are created and categorized their uses.  Chapters-2 and 3 investigate the ethics and 
legalities surrounding this contentious technology.  The author concludes that these experiments 
should be allowed to continue with tight NIH and FDA oversight to ensure careful consideration 
for the well being of the transgenic animals involved, and that patenting transgenic animals 
provides necessary legal protection to allow further transgenic research to continue.  
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Chapter-1: Transgenic Applications 
 
A transgenic animal is a type of animal engineered to incorporate a foreign gene into its 
genome for the purpose of giving it new properties.  This technology resulted from the explosion 
of molecular biology techniques in the 1970‟s and 1980‟s, and has created a variety of new 
animals that benefit society.  The purpose of this chapter is to categorize the types of transgenic 
animals created to date, as an introduction to subsequent chapters on the impact of the 
controversial technology on society.  Transgenic animals can be divided into five main 
categories: disease models, transpharmers, xenotransplanters, food sources, and scientific 
models.  
 
Disease Models 
 Disease models have been engineered to mimic some aspect of a human disease, to allow 
a better understanding of disease formation, and to test potential therapies.  These models hold 
great promise for the study of human pathology, and in some cases are required intermediate 
steps for testing therapies prior to human testing. These animals provide a living system that can 
be used to acquire new information about a disease, with the ultimate goal of testing new 
vaccinations and treatments on laboratory specimens before moving onto human trials. A 
number of human diseases have been successfully been mimicked in laboratory animals, 
including Alzheimer‟s disease, cancer, Parkinson‟s disease, ALS, cystic fibrosis, and AIDS.  
Some of these are discussed below.  
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Alzheimer’s Mouse 
Named for German physician Alois Alzheimer, Alzheimer‟s disease (AD) is the most 
common form of cognitive degeneration.  In November of 1906, Dr. Alzheimer presented the 
case of Frau August D, a patient with memory loss, delusions of suspicion, and a diminishing 
capability of verbal communication. She became a patient of Alzheimer in 1901, was bedridden 
only a few years later, and died in spring of 1906.  In simple terms, Alzheimer‟s disease results 
in a progressive destruction of brain cells, and is ultimately fatal.  While the complete 
mechanism of cell death has not been uncovered, scientists have noticed two hallmarks in those 
afflicted with the disease, senile plaques and neurofibrillary tangles.  Senile plaques contain 
remnants of a toxic -amyloid protein (A) that accumulates between nerve cells in the brain to 
initiate the disease.  Neurofibrillary tangles are composed of a -protein that forms within the 
dying cells, and result from cell death pathways activated by the A.  While plaques and tangles 
occur at low levels in those without Alzheimer‟s, they tend to develop rapidly in those with the 
disease, especially in parts of the brain responsible for memory and learning.  Currently, an 
estimated 5.3 million Americans live with Alzheimer‟s, and the disease has no cure. 
(Alzheimer‟s Association, 2004)  
 In 1995, Professor David S. Adams of the Worcester Polytechnic Institute (in partnership 
with the former Transgenic Sciences, Inc.) became the first team to successfully replicate 
Alzheimer‟s disease in a mouse model. The mouse was designed to express amyloid precursor 
protein (APP) that forms toxic A, in the same areas of the brain affected in Alzheimer‟s (Games 
et al., 1995).  In addition, the form of APP used mimicked an early-onset family in Indiana (the 
Indiana mutation) that develops the disease in their 40‟s.  The experiment proved that A 
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formation is sufficient to initiate the disease, and provided a convenient model to test drugs for 
blocking or reversing disease formation. 
Less than four years later, researchers in San Francisco used this mouse model to develop 
a vaccine against A to prevent senile plaque deposition (Schenk et al., 1999). The vaccine 
decreased the concentration of existing plaques, even in older subjects with severely advanced 
pathology, and was later shown to improve cognitive function.  To confirm the vaccine‟s 
effectiveness, the control group (mice who received an unrelated vaccination) showed advanced 
neuritic dystrophy and astrocytosis. Subjects who had been treated from a young age onward 
contained non traces of A, and showed no apparent health or behavioral complications after 
immunization (Jones, 2000). 
 
Oncomouse 
In the early 1980s, researchers from Harvard Medical School produced one of the world‟s 
first transgenic animals with funding from Dupont.  Appropriately named Oncomouse, the 
specimen had been genetically altered to rapidly develop cancer (Stewart et al., 1984).  A 
recombinant activated oncogene sequence was introduced into the somatic and germ cells of 
mice for the purpose of studying different treatments of tumor formation (Bioethics and Patient 
Law, 2006).  This mouse line received additional publicity in 1988 when Oncomouse received 
the first animal patent (discussed in Chapter-2).  Philip Leder, of the National Institute of Health, 
one of the Oncomouse inventors, described Oncomouse as “the key model system for studying 
cancer, and for testing the effectiveness of novel cancer therapeutics” (Stern, 2000). 
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AIDS Mouse 
Another important disease model is the AIDS mouse.  The HIV virus that causes AIDS 
normally only infects humans and chimpanzees. But limiting factors such as high maintenance 
costs, and a dwindling population in their natural habitat, made primates ill-suited for laboratory 
research.  Additionally, the virus does not cause full blown AIDS in chimps.  
Although mice are easily maintained at a low cost, they naturally lack the CD4 and 
CKR5 receptors that HIV binds to enter cells to cause infection (Science News, 1988).  A 
transgenic rat AIDS model was created at the Baylor College of Medicine in 2001 by injecting 
newly fertilized eggs with a mutated version of HIV (that could not replicate), and implanting the 
modified eggs into the uterus of a foster mother.  The subsequent offspring showed evidence of 
HIV expression, and the characteristic immune dysfunction of AIDS (Reid et al., 2001). 
The creation of AIDS mouse provides a huge opportunity for researchers, and provides 
hope to the estimated 30.8 million adults and 2 million children across the globe currently living 
with HIV/AIDS (AVERT, 2007).   Not only is the specimen completely safe to handle (due to 
the inability to transmit the virus), its use as a biological model can aid in finding new treatments 
for AIDS, and could eventually lead to a cure. 
 
Transpharmers 
 Transpharmers are genetically modified to express a specific protein in their blood, eggs, 
or milk. Since milk is easy to obtain from female animals, and the secreted produce does not 
enter the blood to affect the animal‟s physiology, the mammary gland (classified as a “natural 
secretion organ”) is more frequently used for production.  A special promoter is used to help 
ensure the inserted transgenic DNA will only be “turned on” during milk production, and not 
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expressed in other tissues, thus a transpharmer host should remain normal and healthy while 
expressing the desired protein (GTC Biotherapeutics, 2006). Transpharmers could allow for the 
manufacturing of vital nutrients, enzymes, antibodies, and protein-based human therapeutics to 
become less cost prohibitive, thus becoming more available to patients in need of medication.  
Cows, sheep, goats, and mice, have all been successfully engineered as transpharmers, and are 
favored for their high milk output.  
  In 1991, scientists from GenPharm International engineered the world‟s first transgenic 
bull to carry the human gene for lactoferrin, an iron-containing protein that is vital to infant 
growth and development.  The bull, named Herman, was created by microinjecting early bovine 
embryos with the gene encoding human lactoferrin, and culturing the cells in vitro until they 
reached the blastocyst stage.  The blastocyst embryo was then transferred into recipient cattle. 
Herman was born, matured, and successfully bred (with no subsequent harm from the genetic 
implantation) to become the father of at least eight calves in 1994. This achievement could allow 
for Herman‟s female offspring (and others like them) to produce lactoferrin-rich milk, and 
become a vital source of nutrients for children in developing nations (Biotech Notes 1994). 
 GTC Biotherapeutics, located in Framingham, MA, is responsible for the first 
transgenically produced protein to be approved worldwide.  The protein, called antithrombin, is 
naturally found in human blood, and functions as an anti-clotting mechanism (blood thinner) to 
deactivate several enzymes of the coagulation system. Antithrombin can be used to treat deep 
vein thrombosis with potential applications in oncology, hematology, and various autoimmune 
diseases.  Using pronuclear microinjection, GTC engineered a line of transgenic goats to 
“express a desired protein [antithrombin] in their milk in addition to the many milk proteins it 
already produces.”  The goats were subsequently screened for high levels of antithrombin 
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expression in the mammary gland during milk production.  Goats have an average generation 
time of 18 months (compared to 3 years in cows) and produce an average of 800 liters of milk 
annually. After the goats are milked, the antithrombin is isolated and prepared into a formula 
commercially known as Atryn that can be given to humans.  
 Over the past decade, GTC has published documents evaluating the health and wellbeing 
of all of it‟s transgenic animals, and receives regular inspection (minimum of twice annually) 
from organizations such as the Association for Assessment and Accreditation of Laboratory 
Animal Care International (AAALAC), and the Institutional Animal Care and Use Committee 
(IACUC) (GTC Biotherapeutics, 2006). 
 
Xenotransplanters 
 Xenotransplanters have been engineered to provide organs for transplant into humans.  
The need for Xenotransplanters arose as the demand for clinical organ transplants greatly 
exceeded the supply of available human organs. An estimated sixteen patients die daily waiting 
to receive critical organ transplants (U.S. FDA, 2009). The prefix "xeno” stems from the Greek 
“Xenos”, meaning stranger, and is used in biology to designate species difference (Wikipedia, 
2006).  Therefore, xenotransplantation involves procedures that replace human organs or tissues 
with those from an animal source.  
In Blacksburg, Virginia exists a farm with over 200 pigs.  Due to the chronic shortage of 
organs for transplantation, the DNA of these pigs has been engineered to lack a glycosyl 
transferase gene (alpha-1,3-galactosyltransferase) that encodes an enzyme that adds galactose 
sugars viewed as foreign to humans.  Thus, the organs from these pigs are stripped of the sugars 
that would be recognized as foreign, enabling them to be transplanted into test monkeys. In 
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several testing facilities, the hearts from these pigs have been successfully transplanted into 
baboons, and are able to survive and function in the primates for up to 3-6 months (Fabregas, 
2006). Genetically altered swine kidneys have survived in baboons as well.  
 Another potential application for xenotransplantation includes the 50 million patients 
worldwide who suffer from diabetes. With patients needing constant insulin therapy, and other 
treatments, the total economic burden caused by diabetes in the United States has soared an 
estimated 98 billion dollars annually. Using transgenic pigs designed to lack the genes 
responsible for triggering acute immune rejection, researchers are approximately 2 years away 
from islet cell (insulin producing cell) transplantation trials in humans (Revivicor, 2005).  This 
technology is believed to be technically feasible, and could potentially change the field of 
diabetes treatment forever.  
 
Food Sources  
As the global population increases, so does food consumption. Transgenic food sources 
involve genetically modifying a species‟ genome to incorporate a growth hormone.  In 
aquaculture, this process has been quite successful in several species of trout and salmon, and 
shows promise of helping to accommodate the growing needs of human food consumption. 
 In normal salmon, the gene that regulates growth hormone is activated by light such that 
the fish only grow during the sunny summer months.  Aqua Bounty Technologies developed a 
genetically modified salmon that produces growth hormone year round by attaching a promoter 
sequence to its growth hormone gene.  The transgenic fish look and taste identical to normal 
farmed salmon, but grow twice as fast as their counterparts, and eat less food.  The company‟s 
owner, Elliot Entis, has stated that Aqua Bounty will only market sterile, female transgenic 
 12 
salmon to prevent accidental breeding with native salmon populations, and any resulting 
negative environmental effects (Piquepaille, 2006).  Sterilization in the transgenic fish can be 
achieved through a method called triploidy. The process works by introducing a pressure, 
temperature, or electrical shock to an egg immediately following fertilization, which alters the 
number of chromosomes retained by the zygote.  While triploidy does not ensure sterility in 
males, female specimens produce non-functional ovaries that are completely absent of oocytes 
(Harper, et al., 2006).  Entis is now seeking approval from the Food and Drug Administration 
that could pave the way for marketing his genetically engineered salmon.  
 
 Super Pig (Beltsville Pig) 
 The “Beltsville Pig” was genetically modified to carry human growth hormone (HGH) 
with the hope that the animal would grow faster and leaner than normal pigs without the gene 
therapy (Miller et al., 1989).  The desired results were to increase growth rates and weight gain, 
reduce carcass fat, and increase feed efficiency.  Some of these goals were achieved, in pigs 
weight gain increased by 15%, feed efficiency by 18%, and carcass fat was reduced by 80%.  But 
the animals suffered from several unanticipated health problems, including kidney and liver 
problems, uncoordinated gait, bulging eyes, thickening skin, gastric ulcers, severe synovitis, 
degenerative joint disease, heart disease of various kinds, nephritis, and pneumonia (Rollin, 
1996).   The catastrophic failure resulted in a voluntary moratorium on growth hormone 
experiments in mammals. 
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Scientific Models 
 This very broad class of transgenic animals includes those animals engineered to study 
the function of a specific protein by over-expressing the protein, or by knocking out its 
expression, to observe the biological effects in vivo.  Such animals have immensely added to our 
biological knowledge of protein functions. 
 
Smart Mouse 
 In 1999, Joseph Tsien, a neurobiologist from Princeton University, performed an 
experiment to investigate the effect of overexpressing a NR2B protein believed to be responsible 
for improved synaptic function (Tang et al., 1999).  Tsien and his colleagues found that 
overexpressing NR2B produces a type of NMDA receptor, similar to the type produced by the 
embryonic brain, that more efficiently responds to glutamate neurotransmitter.  Earlier, Tsien 
had created mice that lack the NR2B gene in a small region of the brain, and observed their 
impaired learning and memory, formulating the hypothesis that NR2B is important in this 
process.  Then he later performed the over-expression experiment to two mice he named 
“Doogie,” (after the smart TV character Doogie Houser).  The mice showed increased 
performance on maze tests and preserved certain features common to juvenile mice. This new 
strain of mice confirmed the NR2B gene‟s direct correlation to learning and memory, and in the 
long-term could be used to enhance mental and cognitive attributes in people, particularly those 
suffering from dementia and other mental disabilities (Harmon, 1999). 
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Chapter-2:  Transgenic Legalities 
 
Introduction to U.S. Patent Law 
A patent is an exclusive set of rights granted to a patentee to prevent unauthorized 
manufacturing, marketing, or distribution of a material. The first United States Patent Act of 
1790 defined a patentable material as “any new and useful art, machine, manufacture, or 
composition of matter” (Ladas & Parry (2003).  Over the next 220 years, patent laws were 
extensively altered to accommodate changes and advancements in technology, and our 
understanding of the term “composition of matter” has also changed dramatically. We know that 
a transgenic animal is one that is not found in nature, and must be “invented” or created by a 
third party (it is also comprised of matter). Under this context, is a transgenic animal considered 
patentable subject material? Legislation regarding transgenic animals has largely been shaped by 
ethical concerns. This chapter focuses on the effects of transgenic technology on society, via a 
discussion of the origins and development of transgenic patents. 
Currently, the United States Patent and Trademark Office (PTO) lists its conditions for 
patentability pertaining to non-obvious subject matter.  Section 35 U.S.C. 103 (3) of the U.S. 
Patent laws defines the term “biotechnological process” as: 
 “(A) a process of genetically altering or otherwise inducing a single-or multi-
celled organism to: (i) express an exogenous nucleotide sequence, (ii) inhibit, 
eliminate, augment, or alter expression of an endogenous nucleotide sequence, or 
(iii) express a specific physiological characteristic not naturally associated with 
said organism; (B) cell fusion procedures yielding a cell line that expresses a 
specific protein, such as a monoclonal antibody; and (C) a method of using a 
product produced by a process defined by subparagraph (A) or (B), or a 
combination of subparagraphs (A) and (B).” (U.S. Patent and Trademark Office, 
2008) 
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Thus, based on current patent laws (not in effect for the 1980‟s landmark Oncomouse 
court case), the process of creating transgenic animals to over-express a particular protein, or to 
not express a particular protein (knockouts) is patentable, as is the creation of a cell line 
expressing a specific protein, or the method of using a transgenic product. 
 
Explanation of an Animal Patent 
A company may require the protection of an animal patent to prevent customers from 
simply buying one animal and breeding as many others as they like.  Such a practice could 
hinder biological research by taking away any profit incentive for a company to create transgenic 
animals.  An animal patent covers animals whose genomes have been integrated with a particular 
gene sequence and who do not exist as any natural species. Once a company has been issued a 
patent, it can prohibit anyone else from using or selling the transgenic animal without the 
company‟s permission until expiration 17 years later.  The patent can also extend to cover the 
pharmaceutical antibodies or proteins produced by the animal. If any offspring are proven to 
possess the particular gene sequences and exhibit the same traits described by the patent, they are 
also protected by the same restrictions (Andrews, 1993). 
 
First Patent on a Living Organism, 1930 
The Plant Patent Act of 1930 (PPA) established the first patent to a living organism. The 
law granted regulatory rights for new varieties of asexually propagated plants (but not those 
which reproduce through seed germination). Thomas Edison and Luther Burbank were among 
the better-known early advocates of the PPA.  With the enactment of the PPA, congress extended 
the same kind of protection to plant inventions that had long been available to industrial 
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inventions (Kjeldgaard, 1996).  Writer R. Cook, in the Journal of Heredity commented on the 
passage of the PPA three years later. “It is a little hard for plant men to understand why [patent 
laws] of the Constitution should not have been earlier construed to include the promotion of the 
art of plant breeding. The reason for this is probably to be found in the principle that natural 
products are not patentable” (Cook, 1933).  After the legislation passed to allow the first patent 
of a living organism, so began the controversy and ethical concerns that would continue to shape 
other such laws. 
 
 First Patent on a Microorganism:  Diamond v. Chakrabarty, 1980 
 Genetic engineer Ananda Chakrabarty, an employee of General Electric, developed a 
remarkable bacterium in 1972 that was able to digest crude oil into simpler substances that could 
serve as food for other aquatic life.  This bacterium has applications for efficiently treating oil 
slicks without creating environmental problems.  Chakrabarty derived his bacterium from the 
Pseudomonas genus, and proposed a possible use in the treatment of oil spills. In 1980, 
Chakrabarty sought a patent for his bacterium, now known as B. cepacia, but was denied by a 
patent examiner who argued that microorganisms are “products of nature,” and that U.S. patent 
law did not allow living things to be patentable subject matter (Diamond v. Chakrabarty, 1980). 
Chakrabarty appealed his case to the United States Court of Customs and Appeals, who 
voted in Chakrabarty‟s favor, stating that patent law did apply to microorganisms. Sidney 
Diamond, the commissioner of Patents and Trademarks appealed to the Supreme Court, and 
Diamond v. Chakrabarty ensued in March of 1980.   On June 16, 1980, the Supreme Court ruled 
5-4 in Chakrabarty‟s favor.  Chief Justice Warren E. Burger wrote that: 
 “Whoever invents or discovers any new and useful process, machine, 
manufacture, or composition of matter, or any new and useful improvement 
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thereof, may obtain a patent therefore, subject to the conditions and requirements 
of this title.” Under this context, “A live, human-made micro-organism is 
patentable subject matter under [Title 35 U.S.C.] 101. [The] respondent's micro-
organism constitutes a „manufacture‟ or „composition of matter‟ within that 
statute.” (Diamond v. Chakrabarty, 1980) 
 
 
First Patented Animal:  Dupont and Harvard’s Oncomouse 
 Only four years after Chakrabarty‟s case, in June of 1984, geneticists Dr. Philip Leder 
and Dr. Timothy A. Stewart of Harvard University filed for the first American patent on a 
transgenic animal. Harvard University scientists Timothy Stewart and Philip Leder developed 
transgenic “Oncomouse” that was genetically predisposed to developing cancerous tumors. The 
researchers inserted an activated human oncogene into the mouse genome and observed 
increased development of neoplasms (Leder and Stewart, 1984). Harvard applied for a patent for 
Oncomouse in the summer of 1984, but received negative publicity from animal rights groups 
who observed the obvious suffering to the mice that developed tumors (PETA, 2008).  
 In 1988, the United States Patent and Trademark Office granted Patent 4,736,866 (filed 
June 22, 1984) to Harvard College. The document defined the extent of the patent‟s protection to 
include “[the] transgenic non-human mammal whose germ calls and somatic cells contain a 
recombinant activated oncogene sequence introduced into said mammal…” (Bioethics and 
Patent Law, 2006).  The patent claimed the methods used to copy the oncogene, the fertilized 
mouse egg containing the foreign DNA, and the fully developed Oncomouse and its descendants 
(Shorett, 2009).  
 Years later, Harvard and Dupont signed a memorandum of understanding, giving Dupont 
exclusive rights to Oncomouse, and allowed the company to control and restrict its use by 
researchers.  Dupont allowed private organizations such as the Taconic Farms, Inc. to obtain 
licenses to handle Oncomouse, but scientists complained that the fees Taconic charged for the 
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mouse were so high it prohibited research, and the company was criticized for their aggressive 
licensing agreements (Taconic, 1998).  As a result of Dupont‟s and Taconic‟s “anti-competitive 
practices”, MIT, and the University of California ended research agreements previously made 
with them, and The San Francisco Chronicle wrote in 2002 that Dupont was “impeding the war 
on cancer by charging high fees to companies, imposing unusually strict conditions on university 
scientists, and pushing an overly broad interpretation of which lab mice the patents cover” 
(Shorett, 2009). 
Despite significant public ethical concerns, Stewart and Leder subsequently received two 
more patents covering their methods of preparing and testing the transgene.  Although dozens of 
new applications were submitted, the U.S. Patent office did not issue another animal patent until 
almost five years after the Oncomouse trial (Andrews, 1993).  However, as of 2007, using the 
Oncomouse case as precedent, more than 660 patents have been issued on animals since 1988 
(Letterman, 2007). 
 
Transgenic Patent Policies of Other Nations 
Oncomouse in Canada 
With respect to the Oncomouse case in Canada, in 1993, patent 1,341,422 was granted to 
Harvard College allowing modified claims that covered the process of creating the mice but not 
the mice themselves.  However in 2000, the Canadian Federal Court of Appeals overturned this 
decision, ruling 2-1 that both the process and the mouse were eligible for a full patent, although 
the court also asserted that this decision did not include patentability of animals higher than 
mice, including human beings (Ching, 2003). 
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By 2002, after public criticism of the 2000 court ruling allowing mouse patents, the 
Oncomouse case was elevated to the Canadian Parliament. During Harvard College v. Canada, 
the Supreme Court of Canada decided against allowing a patent on animals. The court defined 
the term “composition of matter” as materials and ingredients that had been mixed together by a 
person, so under this context the oncogene sequence that had been inserted into the mouse 
embryo could serve as patentable material, but the body of the mouse itself could not. The court 
described patenting of animals as “ a radical departure from the traditional patent regime, and the 
patentability of such life forms is a highly contentious matter that raises a number of extremely 
complex issues” (Mitchell and Somerville, 2002). 
The Canadian Parliament‟s ruling against Oncomouse dealt a heavy blow to Canadian 
biotechnical companies who were awaiting patents on plants and animals for pharmaceutical 
research. Harvard criticized the decision, stating the companies were being deprived of legal 
protection for their inventions leaving “Canadian scientists at risk of being left behind from their 
colleagues around the world” (Ching, 2003).  To this date, Canada remains the only 
industrialized nation to openly ban animal patents.  
 
Oncomouse in Europe 
 After a similar process of verdicts and appeals, the European Patent Office (EPO) 
eventually approved Oncomouse for a patent in October of 1991. While the case itself was very 
complex, it incorporated the concept of a utilitarian balancing test that weighed the ordre public 
(moral objections) against the possible societal benefits of an application (Bioethics and Patent 
Law, 2006), and this will be discussed further in Chapter 3, Transgenic Ethics.  
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FDA Approval of Transpharmer Products 
The issues surrounding transgenic legalities are not limited to a debate over whether life 
should be patented.  On February 6, 2009, the U.S. Food and Drug Administration issued its first 
approval for a biological product derived from genetically engineered animals. The advisory 
committee of the FDA declared ATryn (an anti-clotting drug from the milk of transpharmer 
goats) to be safe and effective.  The FDA also sought advice from several outside sources, 
including the Center for Veterinary Medicine (CVM) who conducted a thorough investigation 
and assessed the stability of the recombinant DNA construct in the animals‟ genome.  Following 
their investigation, the CVM Director stated: “We have looked carefully at seven generations of 
these GE goats; all of them are healthy and we haven't seen any adverse effects from the rDNA 
construct or its expression. I am pleased that this approval makes possible another source of an 
important human medication” (FDA, 2009). 
 Other companies, like AquaBounty Technologies have been seeking FDA approval for 
almost a decade for their strain of transgenic salmon for use as a food source. These salmon 
mature much faster than native salmon, which can take ten years to reach full maturation and 
begin breeding.  Before granting approval for this controversial food-source, the Food and Drug 
Administration must conduct a full assessment of any risks associated with this product, 
including what happens if the aquafarmed salmon escape into the environment and breed with 
wild type salmon. The FDA staff includes experts in environmental science and biology who 
analyze hundreds of possible environmental impacts (AquaBounty, 2009). 
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Chapter-2 Conclusions 
While some individuals may view animal patents as an infringement on the sanctity of 
life, others recognize that transgenic animals are created for the benefit of human health and thus 
deserve the protection granted by a patent.  The author of this IQP believes that by creating and a 
patenting a transgenic animal that specifically benefits society (such as serving as a cancer 
model), research that benefits society gets protected. Ultimately the information learned from 
such transgenic animals will help minimize all animal suffering in laboratories.  
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Chapter 3: Transgenic Ethics 
 
Since the beginning of civilization, human imagination has dreamt beyond traditional 
species boundaries. Ancient Greeks imagined the griffin, with the body of a lion and the head 
and wings of an eagle. The Egyptian sphinx, perhaps the most famous example, had the head of a 
human on the body of a lion to represent wisdom and strength (Kimbrell, 1994). While 
transgenic technology is so powerful it may only be limited by the constraints of human 
imagination, ethical concerns limit what types of animals should actually be created.  The 
purpose of this chapter is to discuss the ethics of transgenesis. 
 
The Utilitarian Balancing Test 
 In order to make an argument in favor or against a specific transgenic animal, one must 
consider a utilitarian balancing test.  The purpose of the test is to assess the potential benefits to 
society associated with a particular transgenic animal, and weigh that against any negative 
aspects or ethical objections.  One could consider positive examples as advancement of our 
medical knowledge, or the development new pharmaceutical treatments to save lives.  Negatives 
might include concerns like public unease regarding the ethical treatment of the animals, or 
potential pain suffered by an animal.  If the likelihood of substantial medical benefits outweighs 
the moral concerns, then one can argue in favor of continuing to experiment with the respective 
transgenic animal (Christiansen and Sadoe, 2000). 
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Alzheimer Mouse Ethics 
 Alzheimer‟s Disease (AD) has been referred to as “the long goodbye.”  A nursing home 
staff member described AD in a New York Times interview as “ a cataclysm” that “tests the 
human spirit” as caregivers helplessly watch victims fade into the incoherent fog of the disease 
(Gross, 2004).  The Alzheimer‟s Association released a recent report that revealed some startling 
statistical information about the disease.  An estimated 5.3 million Americans have AD, making 
it the 7
th
 leading cause of death.  The total cost of Alzheimer‟s and other dementias to Medicare, 
Medicaid, and private business amounts to 148 billion dollars, annually. A new case of the 
disease is diagnosed every 70 seconds, and 9.9 million caregivers, such as friends and family of 
the victims, are not paid for their services. (Alzheimer‟s Association, 2009)  
From a utilitarian standpoint, the Alzheimer mouse disease model developed by Professor 
David Adams at WPI and his colleagues at the former Transgenic Sciences Inc (Games et al., 
1995) (as discussed in Chapter-1) is a great benefit to society.  The mouse line has taught us that 
the production of human β-amyloid protein in a mouse brain is sufficient for initiating the 
disease, and has provided a model for rapidly screening drugs for blocking β-amyloid 
production. Since the creation of the Alzheimer‟s mouse, Elan Pharmaceuticals Inc. (San 
Francisco) has already used it to develop five different vaccines and inhibitors capable of 
removing senile plaques from neurological tissue (Elan, 2009).  They are currently beginning 
human clinical trials that will lead to a better understanding of AD, and may help uncover an 
eventual cure.  The costs that would be saved from complete eradication of Alzheimer‟s are 
astronomical. 148 billion dollars is enough money to modernize the U.S. railway system. On a 
global scale, it‟s enough to maintain freshwater supply systems and sanitation systems for the 2.5 
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billion people who still do not have ready access to clean drinking water (Agence France-Presse, 
2009). 
With respect to the wellbeing of the transgenic mice, no signs of pain have been observed 
to date.  They eat, sleep, and reproduce normally, and show no signs of physical suffering or 
abnormal behavior. Aside from slightly poor performances on maze testing, Alzheimer mice 
appear to be pain-free (Adams, 2009). 
 
Superpig Ethics  
 Superpig was created to potentially benefit society by providing a means to increase meat 
production (Miller et al., 1989).  Based on the classic 1982 experiment of Ralph Brinster of the 
University of Pennsylvania who engineered a “super mouse” to contain a human growth gene, 
because the mouse did not appear to suffer from the transgene, researchers assumed that what 
worked for mice would work for livestock, and that “super pigs” could produce more meat at a 
lower cost, in less time.  But the first transgenic super pig was a disaster. Researchers were 
unable to accurately predict the effect of the extra production of growth hormone on the pig‟s 
metabolism, and critics called the resultant creation a “super cripple”. “Excessively hairy, 
lethargic, riddled with arthritis, apparently impotent, and slightly cross-eyed, the pig rarely even 
stood up” (Kimbrell, 1994). 
In the case of the superpig, ethical concerns regarding the animal‟s suffering greatly 
outweighed any benefits that a larger, leaner breed of pig would have on society.  No real 
purpose for the animal existed, since farmers could breed more pigs as an alternate method to 
increasing meat production.  Since “super pig” scored unfavorably on the utilitarian balancing 
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test, scientists agreed on a voluntarily moratorium on growth hormone experiments in livestock 
(Adams, 2009).  
 
Oncomouse Ethics  
 Not every transgenic animal can easily be balanced on a utilitarian scale. Specifically, the 
case of the Oncomouse falls into an ethical “gray area.” On one hand, Oncomouse (discussed in 
detail in Chapter-1) could be used to screen new treatments for cancer, to help lead to finding a 
cure, and has already taught us large amounts of information on oncogenesis or why tumors 
form.  But conversely, the mice can suffer considerably from their genetic modification.  
 Statistics show that one out of every three Americans will be diagnosed with cancer at 
some point during their lifetime, making it the second leading cause of death.  In 2008, patients 
spent 78 billion dollars fighting cancer.  Avastin, a treatment for colorectal cancer, costs $4,400 
for a monthly dosage alone (ACS, 2009).  
 With respect to pain suffered by the mice, animals are unable to clearly communicate 
their levels of pain or distress, but many feel that their perception and tolerance is analogous to 
that of human beings. Since a cancer patient‟s levels of pain can influence morality as well as 
morbidity, one can expect that Oncomouse specimens experience significantly high levels of 
pain and suffering from their affliction, especially if the tumors are allowed to progress to 
advanced stages prior to euthanasia.  
 Because cancer affects so many people, this author believes that new treatments and 
preventatives should be researched at all costs, but scientists must also consider the wellbeing of 
the animals used for experimentation. Preventative steps must be taken to minimize the distress 
of the animals by using painkillers whenever possible to reduce suffering.  In addition, university 
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and corporate IACUC committees should enforce the early euthanasia of the mice prior to 
advanced tumor formation.  The author feels that the potential benefits of cancer research do 
outweigh the animals suffering in this case.  By creating an Oncomouse, scientists have created a 
specific test subject specifically for researching cancer treatments, which eliminates the need to 
test on other species. This will ultimately reduce the amount of human subjects that will need to 
be tested in clinical trials, and thus minimize the total amount of suffering.  
 
Chapter-3 Conclusions 
 This chapter describes the ethical concerns associated with three specific cases of 
transgenic animals. In some cases, like the Alzheimer‟s mouse model, vital research can be 
conducted without causing obvious harm to the mice involved. Therefore, the Alzheimer model 
passes the utilitarian balancing test, and research should be allowed to continue on that model.  
In instances such as the “super pig,” significant animal suffering is caused for no real benefit, so 
that research was rightfully terminated.   For more complicated instances, such as the 
Oncomouse, steps must be taken to reduce the animal‟s suffering whenever possible by 
administering pain killers, and humane euthanasia should be considered before the disease is 
allowed to progress to levels that would cause suffering to the mice.  
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PROJECT CONCLUSIONS 
 
 
 
 Transgenic research has lead to a much greater understanding of human disease, gene 
function, and methods for producing pharmaceutical proteins. The author believes that overall, 
the potential benefits of transgenic animals outweigh many of the ethical concerns regarding the 
treatment of the animals in laboratories. However, strict moral consideration should be given to 
the treatment of the animals used in each experiment, and precautions should be taken to 
minimize animal suffering  (by using painkillers or euthanasia if necessary). Transgenic animals 
should only be created to benefit society, and cases that involve animal suffering for no real 
purpose, like the superpig experiment, should be promptly discontinued.  
The author agrees with the new FDA guidelines for transgenic patents, and believes that 
legislation should be passed to ensure safe and responsible use of transgenic animals, while 
allowing patents to protect the interests of the biotechnology companies who developed the 
specific animal so that further research can continue. Transgenic animals should be eligible for 
patents, as strict governmental regulation of this technology will help prevent accidental 
environmental release of the animals, such as an unwanted breeding of aquafarmed transgenic 
salmon with native salmon populations.  
 
